Search
Research
Blinatumomab Added to Chemotherapy in Infant Lymphoblastic LeukemiaKMT2A-rearranged acute lymphoblastic leukemia (ALL) in infants is an aggressive disease with 3-year event-free survival below 40%. Most relapses occur during treatment, with two thirds occurring within 1 year and 90% within 2 years after diagnosis. Outcomes have not improved in recent decades despite intensification of chemotherapy.
Research
Bile Acids and Microbiota Interplay in Pancreatic CancerEvidence suggests the involvement of the microbiota, including oral, intra-tumoral and gut, in pancreatic cancer progression and response to therapy. The gut microbiota modulates the bile acid pool and is associated with maintaining host physiology. Studies have shown that the bile acid/gut microbiota axis is dysregulated in pancreatic cancer.
Research
In vivo loss of tumorigenicity in a patient-derived orthotopic xenograft mouse model of ependymomaEpendymomas (EPN) are the third most common malignant brain cancer in children. Treatment strategies for pediatric EPN have remained unchanged over recent decades, with 10-year survival rates stagnating at just 67% for children aged 0-14 years. Moreover, a proportion of patients who survive treatment often suffer long-term neurological side effects as a result of therapy. It is evident that there is a need for safer, more effective treatments for pediatric EPN patients.
News & Events
Philanthropic legacy dedicated to seeing all kids with cancer survive and thriveOne of WA’s biggest ever philanthropic gifts will transform childhood cancer research and treatment by improving outcomes for children with cancer and discovering more effective and less toxic treatments.
News & Events
Pioneering research could be key to keeping cancer in checkCancer research is being reimagined after a collaboration between The Kids Research Institute Australia, the Peter Doherty Institute for Infection and Immunity.
News & Events
The Kids Research Institute Australia researchers share in TPCHRF fundingEight The Kids Research Institute Australia researchers are among those who have received grant funding from the Telethon-Perth Children’s Hospital Research Fund (TPCHRF).
News & Events
Cancer researcher to use Forrest Fellowship to tackle high rates of relapse after sarcoma surgeryA The Kids Research Institute Australia researcher aiming to reduce the high rate of relapse in children after cancer surgery has won a prestigious post-doctoral fellowship from the Forrest Foundation.
News & Events
PhD pathway program ensuring bright future for clinical research in WATwo outstanding Perth Children’s Hospital clinicians will be supported to pursue a career in medical research, paving the way for more clinician-scientists in Western Australia.
Research
Survival Outcomes of Children with Relapsed or Refractory Myeloid Leukemia Associated with Down syndromeChildren with Down syndrome (DS) are at a significantly higher risk of developing acute myeloid leukemia, also termed myeloid leukemia associated with DS (ML-DS). In contrast to the highly favorable prognosis of primary ML-DS, the limited data that are available for children who relapse or who have refractory ML-DS (r/r ML-DS) suggest a dismal prognosis. There are few clinical trials and no standardized treatment approach for this population.
Research
Acute Lymphoblastic Leukemia in Infants: A Distinctive, High-Risk Subtype of Childhood Acute Lymphoblastic LeukemiaAcute lymphoblastic leukemia (ALL) in infants younger than 1 year of age is an aggressive, high-risk subtype of childhood ALL. Infant ALL with KMT2A-r is characteristically poorly responsive to chemotherapy and hematopoietic stem cell transplantation. New strategies, such as molecularly targeted therapies and immunotherapies, are in development and show promise in preclinical models and early phase studies.